⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820646 | 0.78 | — | — | |
| SCHEMBL14616426 | 0.76 | — | — | |
| SCHEMBL11543373 | 0.74 | — | — | |
| SCHEMBL162683 | 0.74 | — | — | |
| SCHEMBL3256572 | 0.74 | — | — | |
| SCHEMBL1946300 | 0.74 | — | — | |
| SCHEMBL9653828 | 0.74 | — | — | |
| SCHEMBL11542411 | 0.74 | — | — | |
| SCHEMBL12968245 | 0.71 | CDK1 (0.42) | — | |
| SCHEMBL18519980 | 0.71 | KDM4E (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433258-B1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3433258-B1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3430000-B1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3430000-B1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC (US) | 2022-12-28 | — | — | EP | disclosed |
| CN-108834412-B | Pyrimidines and variants thereof, and uses thereof | 传入制药公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-108779119-B | Pyrimidines and variants thereof, and uses thereof | 传入制药公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11230532-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-10822311-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200239421-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-10662162-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190055202-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | US | disclosed |
| EP-3433258-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | Afferent Pharmaceuticals Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-3430000-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | Afferent Pharmaceuticals Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017165255-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017165255-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017160569-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017160569-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| EP-1165522-A1 | NEUROTROPHIC THIO SUBSTITUTED PYRIMIDINES | Krenitsky Pharmaceuticals, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059893-A1 | NEUROTROPHIC THIO SUBSTITUTED PYRIMIDINES | KRENITSKY PHARMACEUTICALS INC. (US) | 2000-10-12 | — | — | WO | disclosed |